Ignite Creation Date:
2024-05-06 @ 4:07 PM
Last Modification Date:
2024-10-26 @ 2:04 PM
Study NCT ID:
NCT04874935
Status:
COMPLETED
Last Update Posted:
2022-11-15
First Post:
2021-04-29
Brief Title:
The Possible Efficacy and Safety of Lansoprazole Co-administration With Neoadjuvant Chemotherapy in Women With Breast Cancer
Sponsor:
Tanta University
Organization:
Tanta University
Study Overview
Official Title:
The Possible Efficacy and Safety of Lansoprazole Co-administration With Neoadjuvant Chemotherapy in Women With Breast Cancer
Status:
COMPLETED
Status Verified Date:
2022-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Investigation of the possible efficacy and safety of lansoprazole co-administration with neoadjuvant chemotherapy in tumor response in women with breast cancer who will be planned for surgery
Detailed Description:
Several studies revealed that PPIs inhibit not only the HK ATPase in gastric parietal cells but also the vacuolar H ATPase V-ATPase overexpressed in tumor cells the V-ATPase is an ATP-dependent proton pump that transports H across both intracellular and plasma membranes to regulate intracellular and extracellular pH
Co-administration or pretreatment with PPIs could inhibit H transport via the V-ATPase in tumor cells resulting in lower extracellular acidification and intracellular acidic vesicles which increase the sensitivity of the tumor cells to the anticancer agents Moreover the low extracellular pH induces an increased activity of drug efflux pumps P-glycoprotein P-gp which is closely associated with multi-drug resistance MDR of tumors As a consequence there remains a lower concentration of chemotherapeutic drugs in tumor cells and reduced cytotoxic efficacy thus restoring the normal extracellular PH will decrease MDR
Co-administration or pretreatment with PPIs could inhibit H transport via the V-ATPase in tumor cells resulting in lower extracellular acidification and intracellular acidic vesicles which increase the sensitivity of the tumor cells to the anticancer agents Moreover the low extracellular pH induces an increased activity of drug efflux pumps P-glycoprotein P-gp which is closely associated with multi-drug resistance MDR of tumors As a consequence there remains a lower concentration of chemotherapeutic drugs in tumor cells and reduced cytotoxic efficacy thus restoring the normal extracellular PH will decrease MDR
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None